Chan, Wah-Kheong and Tan, Soek-Siam and Chan, Siew-Pheng and Lee, Yeong-Yeh and Tee, Hoi-Poh and Mahadeva, Sanjiv and Goh, Khean-Lee and Ramli, Anis Safura and Mustapha, Feisul and Kosai, Nik Ritza and Raja Ali, Raja Affendi (2022) Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease. Journal of Gastroenterology and Hepatology, 37 (5). pp. 795-811. ISSN 0815-9319, DOI https://doi.org/10.1111/jgh.15787.
Full text not available from this repository.Abstract
The Malaysian Society of Gastroenterology and Hepatology saw the need for a consensus statement on metabolic dysfunction-associated fatty liver disease (MAFLD). The consensus panel consisted of experts in the field of gastroenterology/hepatology, endocrinology, bariatric surgery, family medicine, and public health. A modified Delphi process was used to prepare the consensus statements. The panel recognized the high and increasing prevalence of the disease and the consequent anticipated increase in liver-related complications and mortality. Cardiovascular disease is the leading cause of mortality in MAFLD patients; therefore, cardiovascular disease risk assessment and management is important. A simple and clear liver assessment and referral pathway was agreed upon, so that patients with more severe MAFLD can be linked to gastroenterology/hepatology care, while patients with less severe MAFLD can remain in primary care or endocrinology, where they are best managed. Lifestyle intervention is the cornerstone in the management of MAFLD. The panel provided a consensus on the use of statin, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, sodium-glucose cotransporter-2 inhibitor, glucagon-like peptide-1 agonist, pioglitazone, vitamin E, and metformin, as well as recommendations on bariatric surgery, screening for gastroesophageal varices and hepatocellular carcinoma, and liver transplantation in MAFLD patients. Increasing the awareness and knowledge of the various stakeholders on MAFLD and incorporating MAFLD into existing noncommunicable disease-related programs and activities are important steps to tackle the disease. These consensus statements will serve as a guide on MAFLD for clinicians and other stakeholders.
| Item Type: | Article |
|---|---|
| Funders: | None |
| Uncontrolled Keywords: | Consensus; MAFLD; Malaysia; Malaysian Society of Gastroenterology and Hepatology; Metabolic dysfunction-associated fatty liver disease; MSGH; Multi-disciplinary; NAFLD; Non-alcoholic fatty liver disease |
| Subjects: | R Medicine R Medicine > RC Internal medicine |
| Divisions: | Faculty of Medicine |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 19 Sep 2023 03:37 |
| Last Modified: | 27 Nov 2024 02:49 |
| URI: | http://eprints.um.edu.my/id/eprint/43038 |
Actions (login required)
 |
View Item |
